_uacct = “UA-1399567-1”;
urchinTracker();
Mês: outubro 2012
IMT em Diabéticos
CONCLUSIONS Carotid IMT is a significant predictor of CVD in asymptomatic type 2 diabetic patients, and the combination of FRS and IMT improves the prediction of CVD in these patients.…………………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. Durante o mestrado, fiz centenas de exames de carótidas de diabéticos convicto que não serviria para nada. Agora esse estudo revela valor adicional ao Escore de Framingham! . De acordo com os achados recentes de que parte dos diabéticos não evoluem mal no sistema cardiovascular…………………………………………………………………… Talvez a IMT possa identificar esses pacientes ………………………………………………………………………………………………………………………………………………….
EMBOLIA PULMONAR AO ECO.
AQUI LINK………………………………………………………………………………………………………………………………………………………………………………………………………………………………….. Echocardiography can be used for rapid and accurate risk stratification of patients with pulmonary embolism to appropriately direct the therapeutic strategies for those at high risk. Echocardiography is an ideal risk stratification tool in this regard because of its easy portability to the emergency room or to the bed side. It can be performed at a relatively low cost and at no risk to the patient. Furthermore, echocardiography allows repetitive noninvasive assessment of the cardiovascular and hemodynamic status of the patient and the response to the therapeutic interventions. Right ventricular hypokinesis, persistent pulmonary hypertension, a patent foramen ovale, and a free floating right heart thrombus are echocardiographic markers that identify patients at a higher risk for morbidity and mortality. Such patients warrant special consideration for thrombolysis or embolectomy. ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………..
Medicosweb: Site para médicos
. AQUI. Site para médicos serem encontrados por pacientes novos. .
Olha a nova dona da Amil aí, gente!
. . One of the nations largest health insurers has agreed to pay $50 million in a settlement announced today after being accused of overcharging millions of Americans for health care. The New York attorney generals office launched an investigation after receiving hundreds of complaints about Oxford Insurance and its parent company, UnitedHealth Group, which claims to rely on independent research from across the health care industry to determine reimbursement rates. In actuality though, it relies on Ingenix, a research firm owned by UnitedHealth Group. New York Attorney General Andrew Cuomo says Ingenix has been manipulating the numbers so insurance companies pay less. In a just-released report, he contends that Americans have been under-reimbursed to the tune of at least hundreds of millions of dollars. Although UnitedHealth Group and Oxford Insurance were the only entities investigated, other major insurers use Ingenix, including Aetna, CIGNA and WellPoint/Empire BlueCross BlueShield. Not feeling so well at http://www.michaelmoore.com………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. A UNITEDHEALTH pagou quase 10 bilhões pela Amil. Nos EUA, ela domina com as ressalvas acima. .





